Read the committee members' biographies and registered interests.

Dr Jane Adam, MB BS, MRCP, FRCR

Chair

Consultant Radiologist to St. George 's Hospital, London

More about Jane

Biography

Jane is consultant radiologist to St. George 's Hospital, London with subspecialty interests including Computerised Tomography, Magnetic Resonance Imaging and oncological imaging.

She is former Chairman of both The Clinical Radiology Audit and Standards Subcommittees of the Royal College of Radiologists, former RCR Recertification Lead and previous member of RCR Education Board, Faculty Board and Council.

She was founding Chair of the Audit and Standards Committee of the European Society of Radiology, currently chairs the Professional Organisation Committee, and is a member of the ESR Executive Council.

Registered interests

None


Dr Brian Shine

Vice chair

Consultant chemical pathologist, Oxford Radcliffe Hospitals Truste

More about Brian

Biography

Brian Shine is a consultant chemical pathologist in the Oxford University Hospitals Trust and Honorary Senior Lecturer in the Nuffield Department of Clinical Laboratory Sciences, University of Oxford.

He trained in medicine in Zimbabwe, and in Clinical Biochemistry at St. Bartholomew's Hospital, London, and then worked at Moorfields Eye Hospital, and Stoke Mandeville Hospital.

His clinical interests are endocrinology (particularly neuroendocrine tumours and thyroid cancer), renal stone disease, metabolic bone disease, lipid disorders, and inherited metabolic disorders. His other interests include statistics, evidence based medicine, use of information technology in laboratories, postgraduate medical education, and research ethics.

Registered interests

None


Peter Baker

Public Health Physician, Deputy Director of the Global Health and Development Group, Imperial College London

More about Peter

Biography

Dr Peter Baker is the Deputy Director of the Global Health and Development Group, Imperial College London; the Deputy Director of the international Decision Support Initiative (iDSI); an honorary Public Health Consultant at Imperial College Healthcare NHS Trust, and a Fellow of the UK's Faculty of Public Health.

His research and public health work has focused on bringing together the health and economic professions, methods, data and analysis in order to improve the use of evidence in priority setting in health, for Tower Hamlets’ Local Authority, the NHS, Public Health England, the UK’s Department for International Development and also overseas in South Africa, Rwanda, Tanzania, Sierra Leone, Zambia and Ethiopia.


Dr Minal Bakhai

General Practitioner

More about Minal

Biography

Biography coming soon.

Registered interests

None


Richard M. Ballerand

Lay member

More about Richard

Biography

Richard is a Franco-British health policy advisor. With a dual finance and defence background, degrees in economics, strategy and psychology, a former military liaison officer, he later served as non-exec or trustee on think-tanks, boards and councils.

He chairs his GP’s patient participation group. He is lay member on the NHSx National Data Collaborative for Health and Care, an NIHR Health Technology Assessment Prioritisation committee and the NHSE London Clinical Senate. He is an EMA European patient expert and active health systems networker, with roles on four London NHS Trusts.

Richard draws on extensive lived family experience of British, French and American healthcare systems. Having sustained a traumatic brain injury during his doctoral studies, Richard has a special interest in those with invisible disabilities, and in the challenges facing both ex-military and diverse communities.

Registered interests

None


Angela H. Blake

Head of Health and Value, Pfizer Ltd

More about Angela

Biography

Angela started her career in the NHS as a cardiac nurse. After a couple of years in consulting and completing a Master of Science in Health Economics, she joined the pharmaceutical industry. Over the past 18 years, Angela has gained considerable knowledge in UK health technology assessment (HTA), pricing and market access across a broad range of therapeutic areas. Angela also sits on a number of external Association of the British Pharmaceutical Industry/Department of Health and Social Care advisory groups to influence and shape HTA policy to enable more flexibility in the national medicine assessment frameworks across the UK. In her role as UK Head of Health and Value, Angela currently leads a team of highly technical experts who play a pivotal role in demonstrating the value of our medicines to HTA bodies to secure faster national access.

She is passionate about creating alternative access solutions and patient reported outcomes to ensure that patients benefit from innovation and science.


Dr Justin Daniels

Consultant Paediatrician, North Middlesex University Hospital

More about Justin

Biography

Justin is a consultant paediatrician and neonatologist at North Middlesex University Hospital. His clinical interests are paediatric HIV and paediatric dermatology. He is also the clinical lead for paediatrics. He is an honorary senior lecturer at University College and teaches both undergraduates and postgraduates. He is the designated doctor for child deaths for the London Borough of Enfield.

Registered interests

None.


Andrew Champion

Assistant Director, Evidence Evaluation, Welsh Health Specialised Services Committee

More about Andrew

Biography

Biography to follow.


Dr Steven J. Edwards

Director of Health Technology Assessment, BMJ Technology Assessment Group (BMJ-TAG)

More about Steven

Biography

Steve leads one of the health technology assessment groups, funded by the National Institute for Health Research (NIHR), to conduct independent research to support health policy decision making.

Since 1999, Steve has been involved in exploring methods for evidence synthesis and health economic evaluation. His primary research interests relate to making best use of the available evidence for decision making, with an emphasis on the appropriate design and conduct of studies, aggregation of clinical data, and their use in economic modelling.

Steve is an Honorary Lecturer in Public Health at the London School of Hygiene and Tropical Medicine, a member of the Cochrane Pregnancy & Childbirth Group, and the statistics advisor for diagnostic test accuracy systematic reviews for the Cochrane Skin Group. Until April 2018, Steve was a member of the NICE Diagnostics Advisory Group.

Registered interests

None.


Rita Faria

Research Fellow, Centre for Health Economics, University of York

More about Rita

Biography

Rita is a health economist at the Centre for Health Economics, University of York. Rita has extensive experience in economic evaluation in a wide range of areas including drugs, devices, diagnostic tests and complex interventions in health and social care. Rita’s research interests are in using economic evaluation to inform complex decision problems and non-randomised data.

Registered interests

Non-personal financial interest

March 2019 to present: employer receives funding from the NIHR to undertake a programme of technology assessment for NICE (assessment group, ERG and DAG work). They were awarded, led by the York Health Economics Consortium, the contract on the NICE economic and methodological unit for public health and social care. Rita is involved in some of these projects.

Other interests

February 2017 to November 2018: presented to NICE DSU Masterclass on 'Selecting appropriate methods: the DSU algorithm' and 'Quality of effectiveness estimates from non-randomised studies'. Received a fee for presenting.

October 2016 to present: expert health economic reviewer for the Portuguese Committee for Evaluation of Health Care Technologies (Comissão de Avaliação de Tecnologias de Saúde (CATS)), for INFARMED, which is the Portuguese Health Technology Assessment Agency. In this capacity she conducts a critical appraisal of the economic evidence on drugs seeking reimbursement from the Portuguese National Health Service. The economic evidence is submitted by the manufacturer to INFARMED. She doesn't make decisions about whether the drug is cost-effective nor if reimbursement is warranted. She receives a fee for conducting each critical appraisal.

March 2018 to present: involved in the update of the methods guide for economic evaluation for the INFARMED. No payment received for this work.

Indirect interest

April 2019 to present: teaches a ABPI/NICE/DSU Masterclass each year titled 'Using non randomised data to estimate treatment effects in NICE submissions' for which she receives a fee.


Adrian Griffin MSc, BSc

Vice President, HTA & International Policy, Johnson & Johnson

More about Adrian

Biography

Adrian is VP of Health Technology Assessment and International policy at Johnson & Johnson. Since graduating in health economics he has held a variety of UK, European, and global positions in health economics and reimbursement in both the pharmaceutical and medical device & diagnostic industries.

Registered interests

Direct - financial

2001 to present: employee of Johnson & Johnson


Khalida Ismail

Professor of Psychiatry and Medicine, King’s College London

More about Khalida

Biography

Khalida is a clinical academic psychiatrist at King’s Health Partners. She has a special interest in the epidemiology of psychiatric disorders in diabetes, such as depression, eating disorders and psychotic disorders. She also has a special interest in developing and evaluating interventions to improve diabetes self-management.


Sumithra Maheswaran

Chief Pharmacist, London Ambulance Service NHS Trust

More about Sumithra

Biography

Having completed her pharmacy undergraduate degree at Kings College London, Sumithra has gained extensive experience in clinical pharmacy across hospital and commissioning. She also has a Masters in Business Administration from Imperial College Business School.

Sumithra has particular interest in medication safety, evidence-based medicines and guidelines.

Registered interests

Financial interest

May 2019: Consultancy fee for advisory board 3rd April 2019 regarding a product manufactured by Veriton pharma via Integ Ltd.


John J V McMurray, MD FESC FACC FAHA

Professor of Medical Cardiology, University of Glasgow

More about John

Biography

John is honorary Consultant Cardiologist at the Western Infirmary in Glasgow and has a special interest in clinical trials (particularly in cardiovascular disease but also in diabetes mellitus and chronic kidney disease), guidelines and evidence-based medicine.

Registered interests

Indirect

February 2015 - January 2017: employer, Glasgow University, was paid by Abbvie (who manufacture atrasentan) for his time spent as Steering Committee member for the SONAR trial (using atrasentan) and meetings related to this trial. Abbvie also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he did not receive personal payments in relation to this trial/this drug.

August 2015 - September 2018: employer, Glasgow University, was paid by Kings College Hospital (who have received a grant from KRUK and Vifor-Fresenius who manufacture intravenous iron) for his time spent as steering committee member for the PIVOTAL trial (using intavenous iron) and for running the endpoint adjudication committee for this trial, as well as meetings related to PIVOTAL. Kings College Hospital was paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he did not receive personal payments in relation to this trial/this drug.

October 2016 - January 2019: employer, Glasgow University, was paid by Bayer for his time spent as steering committee member for the PANACHE trial using neladenoson bialanate (BAY 1067197). These payments were made through a consultancy with Glasgow University and he did not received personal payments in relation to this trial/drug.

March 2012 - March 2017: employer, Glasgow University, was paid by Cardiorentis for his time spent as steering committee member and Endpoint committee chair for the TRUE-AHF trial and meetings related to this trial. Cardiorentis also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he did not received personal payments in relation to this trial/drug.

June 2016 - May 2021: employer, Glasgow University, was paid by Amgen for his time spent as steering committee member for the ATOMIC-HF and COSMIC-HF trials and meetings related to this trial. Amgen also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/this drug.

August 2015 - September 2018: employer, Glasgow University, was paid by Kings College Hospital (who have received a grant from KRUK and Vifor-Fresenius who manufacture intravenous iron) for his time spent as steering committee member for the PIVOTAL trial (using intavenous iron) and for running the endpoint adjudication committee for this trial, as well as meetings related to PIVOTAL. Kings College Hospital has also paid his travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to this trial/this drug.

November 2013 - December 2019: employer, Glasgow University, was paid by Theracos for his time spent as principal investigator for the BEST trial and meetings related to this trial. Theracos has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to this trial/this drug.

March 2014 - May 2016: employer, Glasgow University, was paid by Pfizer for his time spent on the data safety monitoring committee for the SPIRE trial and meetings related to this trial. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to this trial/this drug.

May 2016 - July 2021: employer, Glasgow University, was paid by Merck for his time spent on the data safety monitoring committee for the MK-3102 program and for the VICTORIA trial and meetings related to these trials. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to this trial/this drug.

May 2014 - July 2021: employer, Glasgow University, was paid by AstraZeneca (who market dapagliflozin) for his time spent as principal investigator of DAPA-HF and co-principal investigator of DELIVER (trials using dapagliflozin) in heart failure and meetings related to this trial. AstraZeneca has also paid travel and accommodation for these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to this trial/this drug.

April 2016 - December 2019: employer, Glasgow University, was paid by BMS for his time spent as a steering committee member for the STAND-UP clinical trial (using a HNO donor) in heart failure and meetings related to this trial. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to this trial/this drug.

November 2009 - December 2016: employer, Glasgow University, was paid by GSK for his time spent as co-principal investigator and steering committee member, respectively, for the Harmony-Outcomes trial (albiglutide) and two trials, ASCEND-D and ASCEND-ND, using daprodustat, and meetings related to these trials. GSK has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs.

November 2009 - November 2016: employer, Glasgow University, was paid by Novartis for his time spent as executive committee member and then co-principal investigator of ATMOSPHERE trial. Novartis has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs.

February 2015 - February 2020: employer, Glasgow University, was paid by Novartis for his time spent as co-principal investigator of the PARAGON-HF trial. Novartis has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs.

August 2012 - December 2019: employer, Glasgow University, was paid by Novartis for his time spent as co-principal investigator of the PARADIGM-HF trial. Novartis has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs.

December 2015 - December 2019: employer, Glasgow University, was paid by Novartis for his time spent as executive/steering committee member for PARADISE-MI trial. Novartis has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs.

December 2015 - December 2019: employer, Glasgow University, has been paid by Novartis for my time spent as executive/steering committee member for PERSPECTIVE trial. Novartis has also paid travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs.


Sarah Parry RN, BSc (Hons), MSc

Clinical Nurse Specialist in Paediatric Acute, and Palliative Pain Management, Department of Paediatric Anaesthesia, University Hospital Bristol NHS Foundation Trust

More about Sarah

Biography

Sarah is an experienced nurse and Lead Clinical Nurse Specialist for Paediatric Pain Medicine at Bristol Royal Hospital for Children. She has clinical experience in a large variety of paediatric specialities spanning over two decades and has held a number of senior posts within the NHS. Areas of experience include research methodology, systematic reviews and patient safety with a keen focus on medication.

Sarah's qualifications include a masters in pain and advance nursing practice. She also participated in the development of the RCN paediatric pain assessment guidelines.  Additional roles outside of the NHS include:

  • core member of the RCN children and younger person’s pain group
  • honouree lecturer at both Cardiff University and University of the West of England
  • specialist adviser for the Care Quality Commission (CQC).

Sarah has two sons that keep her work-life balance in order. She enjoys most sports, particularly skiing, and keeps fit doing yoga and swimming. But most importantly, she is enthusiastic supporter of welsh rugby!

Registered interests

None.


Ms Pamela Rees

Lay member

More about Pamela

Biography

After obtaining an undergraduate degree and a post graduate certificate in education, Pamela undertook post graduate studies in urban and regional planning at the Architectural Association, London. She is currently studying for her Masters in Public Health at Nottingham University. Panela has taught in secondary, further and adult education for over ten years before going into youth work and then to work with Nottingham City Council in community development and regeneration. She recently retired from working as a Public Health manager with Leicester City PCT is now looking forward to having time to devote to voluntary work, to her garden and to her daughters.

In 2006-7, Pamela was a community member of the NICE Public Health Programme Development Group for the Smoking Cessation Services guidance (NICE PH10). She has worked with ‘disadvantaged' communities for over thirty years and for the past decade the main focus of her work has been on improving patient and public understanding of and involvement in health; improving information and access to appropriate health care services and enabling individuals to take greater responsibility for their own health. Her commitment to social inclusion, equality and supporting public involvement in the forces that shape their lives owes much to this experience and to her personal experience as a carer.

Registered interests

Other interests

June 2017 - present: a public reviewer for National Institute for Health Research and has been appointed to NIHR East Midlands Panel for Patient Benefit. Receives an honorarium for reviewing research funding applications. None of this work has involved drugs or other technologies that have been appraised by TAC A or any other TAC that she's been a member of.


Dr Mohit Sharma

Consultant in Healthcare, Public Health England

More about Mohit

Biography

Mohit is currently a Consultant in healthcare with Public Health England, where he advises the NHS from a population perspective. He is also an Honorary Senior Clinical Lecturer at the University of Oxford and has worked with the Cochrane Collaboration, and the Department of Health. He has also been a NICE Scholar.

Prior to moving into public health, Mohit worked as a surgeon for a number of years in India and in the NHS.

Registered interests

None.


Mr Stephen Sharp

Senior Statistician, University of Cambridge MRC Epidemiology Unit

More about Stephen

Biography

Stephen leads the statistical work for the University of Cambridge MRC Epidemiology Unit, whose goal is to study the genetic, developmental and environmental determinants of obesity, type 2 diabetes and related metabolic disorders and to contribute to the prevention of these disorders. He is a Lecturer for the University of Cambridge MPhil in Epidemiology and Public Health and is a statistical reviewer for journals including “The Lancet” and “Diabetologia”.

Stephen has an MA in Mathematics from Oxford University and an MSc in Medical Statistics from the London School of Hygiene and Tropical Medicine. He has worked as a medical statistician within academia and the pharmaceutical industry, and has experience in the design, analysis and reporting of various clinical trials and observational studies. He has also worked on meta-analysis methods, and taught medical statistics on courses in the UK and abroad.

Registered interests

None


Mr Min Ven Teo

Clinical pharmacist

More about Min

Biography

Min is a clinical pharmacist in a general practice. He was trained at the Welsh School of Pharmacy and subsequently completed an International Masters in Health Technology Assessment and Management under the Ulysses Programme. He spent 2017 to 2018 as a NICE Scholar and is currently a NICE Medicine and Prescribing Associate.

Min has an interest in evidence based medicine and decision making.

Registered interests

Non-financial and personal interest

April 2018 to present: NICE medicines and prescribing associate.


Dr Alice Turner

Consultant in respiratory medicine, Heartlands hospital

More about Alice

Biography

Alice graduated from the University of Leicester. She has done postgraduate training via the Universities of Dundee and Birmingham, completing a PhD focussed on COPD and alpha 1 antitrypsin deficiency (AATD).

She has been a consultant in respiratory medicine at Heartlands hospital since 2011, and is a reader in respiratory medicine at University of Birmingham. In addition she has been a member of the BTS specialist advisory group on COPD and the European Respiratory Society task force on AATD. She has published widely in COPD and AATD, and has ongoing research projects funded by the Alpha 1 Foundation, NIHR, ATS Foundation and others.

Registered interests

Financial interest

2016 to present: consultancy fee received from CSL Behring for advisory board in area of alpha 1 antitrypsin deficiency (AATD); since this condition is rare it is unlikely to affect her work on committee A, as any drugs from this company would likely go to the HST committee instead. Work started 2016 and is likely to continue in financial year 2019-20.

2018: honoraria received for educational talk/event from Chiesi about COPD in 2018, not continuing in 2019-20.

2016 to present: honoraria due to be received for steering committee of an observational study run by Boehringer-Ingelheim in AATD and COPD, started 2016 and study recently extended to 2021.

Indirect interest

2017 to present: employer manages research grant from AstraZeneca for a study in COPD due to end 2020.

2018 to present: employer manages research grant from Chiesi for a study in COPD due to end 2021.

April 2019 to present: employer manages research grant from CSL Behring for a study in AATD. Currently going through contracting, due to end in 2020.


Dr Mark Upton

General Practitioner, Yorkshire Medical Chambers

More about Mark

Biography

Mark works as a GP in North Yorkshire through Yorkshire Medical Chambers. Previously, he was a GP partner on Teesside for 15 years. He trained in medicine at University College London and has postgraduate training in human physiology from King’s College London, epidemiology from the London School of Hygiene and Tropical Medicine and genomics from the University of Birmingham.

Before GP partnership, funded by a Wellcome fellowship in clinical epidemiology at the University of Glasgow, Mark was principal investigator of the Midspan Family Study in Renfrew and Paisley, a population-based study of cardio-respiratory diseases. His main research interest is the early life origin of chronic respiratory diseases. He has published on respiratory, cardiovascular and metabolic epidemiology. Mark has been an editorial writer and peer reviewer for medical journals, and a peer reviewer for research funding bodies.

Registered interests

Financial interest

1999: employee of Pfizer for 2 months. Future pension from Pfizer commensurate with 2 months employment in 1999. For the avoidance of doubt, Mark holds no shares or stock in Pfizer.

2001 to 2014: share-holder in Crestdown Ltd, a company that owned Thornaby Health Centre in Stockton-on-Tees. Shares now sold.

2008 to 2014: profit-share in joint venture between Assura and Woodlands Family Medical Centre in Stockton-on-Tees when Mark was a GP partner there.

Direct non-financial

1995 to present: member of scientific steering committee, Midspan Family Study, University of Glasgow. This is a population based observational study in Renfrew and Paisley. There is no experimental arm, and the study does not involve development of pharmaceutical products or medical devices. Like all epidemiological studies it collected information at baseline about the medication that participants were using at the time.


Dr Roger Whittaker

Clinical Senior Lecturer, Institute of Neuroscience, Newcastle University

More about Roger

Biography

Roger is clinical senior lecturer in the Institute of Neuroscience, Newcastle University, and Honorary Consultant in the Department of Clinical Neurophysiology in the Royal Victoria Infirmary, Newcastle upon Tyne. His clinical and research focus is developing and testing novel diagnostic techniques for patients with neurological diseases.

Registered interests

None.

More information

Find out more about the committee and read papers from previous meetings.

About the Technology Appraisal committee

 

Get involved

Find out when TAC meetings are held and register to attend.